Revelation Biosciences, INC 8-K filings

Revelation Biosciences, Inc. has adopted a stockholder rights plan and declared a dividend of one preferred share purchase right for each outstanding common share.

Revelation Biosciences updates executive agreements, amends bylaws, and reports annual meeting voting results.

Revelation Biosciences, Inc. has published an updated corporate presentation detailing its current strategic initiatives.

Revelation Biosciences announced its first-quarter 2026 financial results, highlighting progress in its Gemini development program and a strengthened cash position.

Revelation Biosciences, Inc. stockholders approved the issuance of common stock related to Class J Warrants, allowing the company to exceed Nasdaq's 20% Exchange Cap.

Revelation Biosciences, Inc. announced its financial results for the three and twelve months ended December 31, 2025, highlighting positive clinical study results for its Gemini program.

Revelation Biosciences announced FDA agreement on a clear approval pathway for its Gemini treatment for Acute Kidney Injury (AKI), including a single adaptive Phase 2/3 study and a composite endpoint.

Revelation Biosciences stockholders approved warrant-related proposals, fixing the expiration date to December 3, 2030, while the company reported positive Phase 1b results for Gemini and outlined plans for a Phase 2/3 AKI study in 2026.

Revelation Biosciences announced its financial results for the three and nine months ended September 30, 2025, highlighting positive clinical study results and an extended cash runway through Q3 2026.

Revelation Biosciences, Inc. canceled its adjourned Special Meeting of Stockholders due to technical voting difficulties and rescheduled it for December 3, 2025.

Revelation Biosciences, Inc. adjourned its Special Meeting of Stockholders from October 15, 2025, to October 29, 2025, due to a lack of quorum.

Revelation Biosciences, Inc. announced it raised approximately $9.6 million in gross proceeds through an inducement offer for the immediate exercise of existing Class H warrants, issuing new Class I warrants in a private placement.

Revelation Biosciences announced positive top-line results from its Phase 1b PRIME clinical study for Gemini in chronic kidney disease patients, demonstrating significant reduction in inflammatory activity and restored cellular response.

Revelation Biosciences, a clinical-stage life sciences company, reported its financial results for the three and six months ended June 30, 2025, highlighting reduced net losses and progress in its Gemini clinical program.

Revelation Biosciences, Inc. has implemented a 1-for-3 reverse stock split effective July 7, 2025, to increase its share price and regain compliance with Nasdaq's minimum bid requirement, while also providing an update on its clinical study progress.

Revelation Biosciences, Inc. announced the results of its Annual Meeting of Security Holders, where shareholders approved several key proposals including discretionary authority for a reverse stock split and an amendment to the equity incentive plan, but rejected a proposal to change the company's corporate domicile.

Revelation Biosciences, Inc. has successfully closed a public offering raising approximately $4 million in gross proceeds to fund its ongoing clinical studies and product development.

Revelation Biosciences, Inc. announced the resignation of Dr. George Tidmarsh from its Board of Directors, citing potential conflicts of interest with his new role at Stanford University School of Medicine and US governmental agencies, with no disagreements with the company.

Revelation Biosciences announced its Q1 2025 financial results, highlighting progress in its Gemini clinical programs and a collaboration in severe burns.

Revelation Biosciences announces positive preclinical results for its drug candidate Gemini, demonstrating a significant attenuation of inflammatory responses in human peripheral blood mononuclear cells.

Revelation Biosciences announced its financial results for the three and twelve months ended December 31, 2024, and provided updates on its clinical programs.

Revelation Biosciences announces it has regained compliance with NASDAQ listing requirements and will continue to be listed on the exchange.

Revelation Biosciences released an updated corporate presentation on February 10, 2025, focusing on its Gemini platform and ongoing clinical studies.

Revelation Biosciences has completed a 1-for-16 reverse stock split, effective January 28, 2025, to consolidate its outstanding shares.

Revelation Biosciences has commenced its Phase 1b clinical study of Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD), with topline data expected mid-year.

Revelation Biosciences has been granted continued listing on the Nasdaq, contingent on a reverse stock split by January 31, 2025, and its stock price reaching $1.00 or above for at least ten consecutive trading days by February 14, 2025.

Revelation Biosciences has regained compliance with Nasdaq's minimum stockholders' equity requirement following a warrant exercise inducement offer.

Revelation Biosciences has successfully raised approximately $4.1 million through a warrant exercise inducement offer, which will support the advancement of its clinical trials for GEM-AKI, GEM-CKD, and GEM-PSI.

Revelation Biosciences announced its financial results for the three and nine months ended September 30, 2024, highlighting progress in its Gemini program and a decrease in cash reserves.

Revelation Biosciences has received notification from Nasdaq regarding non-compliance with minimum bid price and stockholders' equity requirements, potentially leading to delisting.